Structure-based design of lysosome targeting chimeric proteins Ghent University
Classical drug design approaches rely on finding an accessible binding site whose occupancy can exert a pharmacological effect. This condition eliminates many membrane proteins from being “druggable”. In a new venue, “Lysosomal Targeting Chimeras” (LYTACs) use lysosome-shuttling receptors to establish targeted degradation of membrane proteins. In LYTACs, a chimeric ligand comprises a ligand targeting a membrane protein fused to a ligand of a ...